Company intelligence / Profile preview
Oncopeptides AB
Stockholm, Swedenoncopeptides.com ↗
- Ownership
- Private
- Employees
- ~79
- Development stage
- Commercial
01
Overview
Oncopeptides has commercialized its lead product, melflufen (branded as Pepaxti in Europe), for relapsed/refractory multiple myeloma. The drug has demonstrated effectiveness and tolerability in real-world studies among heavily pretreated patients. The company’s next-generation PDC candidate OPD5 recently had its FDA clinical hold lifted and will enter new clinical trials. Additional assets from the SPiKE platform are advancing toward first-in-human studies
- Therapeutic areas
- Oncology
- Modalities
- Peptide Drug Conjugates (PDC)Small Polypeptide-based Innate Killer Engagers (SPiKE)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
No major pharma partnerships publicly disclosed as of May 2025; company open to future partnerships to support development of OPD5 and other candidates
Beyond the preview
Go deeper on Oncopeptides AB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oncopeptides AB.